Ignite Creation Date:
2025-12-25 @ 2:27 AM
Ignite Modification Date:
2026-06-03 @ 9:18 PM
Study NCT ID:
NCT06242834
Status:
RECRUITING
Last Update Posted:
2025-10-22
First Post:
2024-01-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Sponsor:
Northwestern University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
NU 23H05
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | NIH | View |